NavDx® is the first and only clinically validated circulating Tumor Tissue Modified Viral (TTMV®)-HPV DNA blood test that aids in the detection of HPV-driven cancer. The test provides a non-invasive and precise method for identifying HPV-driven cancers before there is clinical or radiographical evidence of disease. Data supporting the clinical validity and utility of NavDx have been published in nearly 20 peer-reviewed publications.

“We are thankful for the opportunity provided by ASTRO to share the latest findings, which emphasize the pivotal role of NavDx in influencing clinical management,” commented Barry M. Berger, M.D., Chief Medical Officer at Naveris. “The data being showcased highlight the critical role circulating tumor HPV DNA assessment can play in shaping patient care strategies. We are enthusiastic about the progress made through our extensive collaborations with a diverse array of partners in the oncology community,” he concluded.

These presentations showcase the utility of NavDx in the management of HPV-driven head and neck cancer at every stage of disease, from treatment response and guidance to surveillance and detection of recurrence:

• 127: Implications of rapid molecular responses to induction chemotherapy (IC) in Human Papilloma Virus (HPV) head and neck squamous cell carcinoma (HNSCC).
  Presenting Author: Misiukiewicz, K.
  Session, Date/Time: Poster Session I | February 29, 2024 | 3:00 PM – 3:30 PM MT

• 112: Comparison of TTMV-HPV DNA to Gold Standard PET for Evaluation of Treatment Response in HPV-Associated Oropharyngeal Cancer after Definitive Treatment
  Presenting Author: Song, R.
  Session, Date/Time: Poster Session I | February 29, 2024 | 3:00 PM – 3:30 PM MT

• 152: Tumor Tissue Modified Viral HPV DNA Monitoring in Patients with Recurrent, Metastatic HPV-driven Oropharyngeal Cancer
  Presenting Author: Hanna, G. J.
  Session, Date/Time: Poster Session II | February 29, 2024 | 4:45 PM – 5:45 PM MT

• 177: Prospective Study of Plasma Biomarker-Guided Surveillance of HPV-positive Oropharynx Cancer Using TTMV-HPV DNA: The SPHERE Study
  Presenting Author: Rettig, E. M.
  Session, Date/Time: Poster Session II | February 29, 2024 | 4:45 PM – 5:45 PM MT

• 132: Detectable Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA in Non-Oropharyngeal Head and Neck Cancers
  Presenting Author: Duffy, E. W.
  Session, Date/Time: Poster Session I | February 29, 2024 | 3:00 PM – 3:30 PM MT

Naveris will also be hosting an Industry Expert Theater at the meeting, focusing on the role of NavDx in optimizing post-treatment surveillance and monitoring for molecular residual disease:

• Action to Insights: A Case-Based Discussion of the Role of NavDx in Post-treatment Surveillance of HPV-Driven OPSCC
  Moderator: Marshall Posner, MD
  Presenters: Meghan T. Turner, MD, and Adam Raben, MD
  Session, Date/Time: Thursday, February 29, 2024 | 5:30pm MT

Naveris and NavDx will be on exhibit at ASTRO MHNCS 2024 at Booth #4.

About Naveris
Naveris is a privately held, commercial stage, precision oncology diagnostics company with facilities in Massachusetts and North Carolina. Since its founding in 2017, Naveris has been committed to improving outcomes for the millions of people at risk of developing viral-induced cancers with novel molecular diagnostics that enable earlier cancer detection. The company operates high-complexity testing clinical laboratories that are accredited by the College of American Pathologists and the New York State Department of Health Wadsworth Center, and are certified under CLIA. For more information on Naveris and the clinical impact of NavDx, please visit www.naveris.com and www.NavDx.com. NavDx has not been cleared or approved by the US Food and Drug Administration (FDA).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240228651560/en/